Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Saint Francis Hospital and Medical Center is among the first hospitals in the nation to offer a new radioactive injection treatment for prostate cancer patients with bone metastases.
"At Saint Francis, we continually strive to be at the forefront of leading-edge treatments and technology. The addition of Radium 223 for our prostate cancer patients helps us continue to deliver the most advanced care to our patients," said Richard C. Shumway, M.D., Senior Attending Physician, Radiation Oncology at Saint Francis Hospital and Medical Center.
Approved by the FDA in May, Xofigo® (radium Ra 223 dichloride) is targeted toward men with advanced prostate cancer whose disease has spread to the bone but not to other organs. The treatment is administered by intravenous injection every four weeks for six months, for a total of six IV treatments. Each treatment takes about 60 seconds and patients are able to leave after a 20-minute visit.
Saint Francis is only one of two hospitals in Connecticut currently offering the new treatment to patients.
Xofigo® is injected into the vein and collects in the bone. The radiation produced by the drug kills the cancer cells and reduces pain caused by bone metastases. Spread of cancer to the bones can also result in other problems, such as fractures (breaks) or high blood calcium levels, which can be dangerous and even life-threatening.
"This is a very promising new treatment," said Alessia Donadio, M.D., Medical Oncologist at Saint Francis. "Early results have shown improved overall survival rates and reduced pain."
According to the American Cancer Society, prostate cancer is the most common cancer among men (after skin cancer), but it can often be treated successfully. The ACS estimates that 238,590 new cases of prostate cancer will be diagnosed this year and approximately 29,720 men will die of prostate cancer. About one man in six will be diagnosed with prostate cancer during his lifetime. Nearly two thirds are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 67.
Xofigo® is co-marketed in the United States by Wayne, NJ-based Bayer Pharmaceuticals and Algeta US of Cambridge, MA.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Prostate / Prostate Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Care, Saint Francis. "Saint Francis Offers New Treatment Choice For Prostrate Cancer." Medical News Today. MediLexicon, Intl., 10 Jul. 2013. Web.
7 Dec. 2013. <http://www.medicalnewstoday.com/releases/263094>
Care, S. (2013, July 10). "Saint Francis Offers New Treatment Choice For Prostrate Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/263094.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.